Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report)’s stock price reached a new 52-week high on Thursday . The stock traded as high as C$2.36 and last traded at C$2.30, with a volume of 216020 shares trading hands. The stock had previously closed at C$2.12.
Cardiol Therapeutics Trading Up 14.6%
The company has a market cap of C$280.11 million, a price-to-earnings ratio of -6.23 and a beta of 0.27. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.39 and a quick ratio of 6.84. The business’s 50-day simple moving average is C$1.63 and its 200-day simple moving average is C$1.63.
Cardiol Therapeutics (TSE:CRDL – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported C($0.05) EPS for the quarter. Research analysts predict that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.
About Cardiol Therapeutics
Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Recommended Stories
- Five stocks we like better than Cardiol Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
